BioNTech Results Presentation Deck

Rationale for selection of BNT162b2 for pivotal Phase 2/3 trial BNT162b2 advanced into Phase 2/3 study, at 30 µg dose level as a 2-dose regimen, based on preclinical and clinical data ● ● ● 20 Preliminary Phase 1/2 data from nearly 120 patients demonstrated favorable overall tolerability profile ▪ A reactogenicity profile that is more favorable than BNT162b1 in both younger and older adults Generally mild to moderate and transient local and systemic adverse events and no serious adverse events ■ Two 30 µg doses of BNT162b2 elicited neutralizing GMTs generally similar to GMTs elicited by BNT162b1 ▪ US and German Phase 1 data BNT162b1 demonstrated GMTs 2.8 and 3.3 times of COVID-19 patient convalescence serum panel at 30 µg (day 28) ▪ In older adults BNT162b2 elicited GMT higher than COVID19 patient sera panel BNT162b2 vaccinated participants displayed favorable breadth of epitopes recognized by T cell responses as compared to BNT162b1 ■ Concurrent induction of high magnitude CD4+ and CD8+ ▪ An evidence for broader T cell immunity and trend for stronger CD8+ T cell responses BNT162b2 Phase 1 data is expected to be published within the upcoming weeks BIONTECH

View entire presentation